Literature DB >> 28718444

Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure.

Elke Pogge von Strandmann1, Silke Reinartz2, Uwe Wager3, Rolf Müller4.   

Abstract

Although most ovarian cancer patients are highly responsive to chemotherapy, they frequently present with recurrent metastatic lesions that result in poor overall survival, a situation that has not changed in the last 20 years. This review discusses new insights into the regulation of ovarian cancer chemoresistance with a focus on the emerging role of immune and other host cells. Here, we summarize the complex molecular pathways that regulate the interaction between tumor and host cells, discuss the limitations of current in vitro and in vivo models for translational studies, and present perspectives for the development of innovative therapies.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28718444     DOI: 10.1016/j.trecan.2016.12.005

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  41 in total

1.  Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.

Authors:  Helen E Burston; Oliver A Kent; Laudine Communal; Molly L Udaskin; Ren X Sun; Kevin R Brown; Euihye Jung; Kyle E Francis; Jose La Rose; Joshua Lowitz; Ronny Drapkin; Anne-Marie Mes-Masson; Robert Rottapel
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

2.  Knockdown of long non-coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells.

Authors:  Hanxue Zou; Hongxia Li
Journal:  Exp Ther Med       Date:  2019-09-30       Impact factor: 2.447

3.  Tumor modeling maintains diverse pathology in vitro.

Authors:  Michael E Bregenzer; Eric N Horst; Pooja Mehta; Caymen M Novak; Taylor Repetto; Catherine S Snyder; Geeta Mehta
Journal:  Ann Transl Med       Date:  2019-12

Review 4.  Designer Self-Assembling Peptide Hydrogels to Engineer 3D Cell Microenvironments for Cell Constructs Formation and Precise Oncology Remodeling in Ovarian Cancer.

Authors:  Zehong Yang; Hongyan Xu; Xiaojun Zhao
Journal:  Adv Sci (Weinh)       Date:  2020-03-20       Impact factor: 16.806

5.  Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer.

Authors:  Austin R Dosch; Samara Singh; Xizi Dai; Siddharth Mehra; Iago De Castro Silva; Anna Bianchi; Supriya Srinivasan; Zhen Gao; Yuguang Ban; Xi Chen; Sulagna Banerjee; Nagaraj S Nagathihalli; Jashodeep Datta; Nipun B Merchant
Journal:  Mol Cancer Ther       Date:  2021-09-13       Impact factor: 6.261

6.  Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion.

Authors:  Jessica Tang; Nicholas Pulliam; Ali Özeş; Aaron Buechlein; Ning Ding; Harold Keer; Doug Rusch; Heather O'Hagan; M Sharon Stack; Kenneth P Nephew
Journal:  Mol Cancer Res       Date:  2018-05-14       Impact factor: 5.852

Review 7.  MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.

Authors:  Maria Luisa Gasparri; Zein Mersini Besharat; Ammad Ahmad Farooqi; Sumbul Khalid; Katayoun Taghavi; Raad Aris Besharat; Claudia Sabato; Andrea Papadia; Pierluigi Benedetti Panici; Michael David Mueller; Elisabetta Ferretti
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-14       Impact factor: 4.553

8.  COL11A1 activates cancer-associated fibroblasts by modulating TGF-β3 through the NF-κB/IGFBP2 axis in ovarian cancer cells.

Authors:  Yi-Hui Wu; Yu-Fang Huang; Tzu-Hao Chang; Chien-Chin Chen; Pei-Ying Wu; Soon-Cen Huang; Cheng-Yang Chou
Journal:  Oncogene       Date:  2021-06-11       Impact factor: 9.867

9.  An Immune-Related Gene-Based Signature as Prognostic Tool in Ovarian Serous Cystadenocarcinoma.

Authors:  Fengjuan Shi; Tongning Deng; Jian Mo; Huiru Wang; Jianxun Lu
Journal:  Int J Gen Med       Date:  2021-07-30

10.  Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance.

Authors:  Elina A Pietilä; Jordi Gonzalez-Molina; Lidia Moyano-Galceran; Sanaz Jamalzadeh; Kaiyang Zhang; Laura Lehtinen; S Pauliina Turunen; Tomás A Martins; Okan Gultekin; Tarja Lamminen; Katja Kaipio; Ulrika Joneborg; Johanna Hynninen; Sakari Hietanen; Seija Grénman; Rainer Lehtonen; Sampsa Hautaniemi; Olli Carpén; Joseph W Carlson; Kaisa Lehti
Journal:  Nat Commun       Date:  2021-06-23       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.